As founders, we work side-by-side with our entrepreneurs to
build companies around innovative science.
Novel therapies for severe, highly
drug-resistant bacterial infections
IPO Nov 2017 (NASDAQ: SPRO)
Restoring metabolic balance to treat
NASH and serious metabolic diseases
– IPO Jun 2019 (NADSAQ: AKRO)
Enhancing synaptic integrity for
treatment of neurologic dis-
orders; sold to Alkermes Nov 2019
Advancing targeted protein
degradation to target previously
“undruggable” disease pathways
Next-generation oncolytic immuno-
therapies for cancer treatment
– IPO Jul 2018 (NASDAQ: REPL)
Scalable, re-dosable, non-viral
gene therapy for genetic diseases
IPO Jun 2020 (NASDAQ: GBIO)
Broadening the reach and
impact of precision medicine
to more people with cancer
Preventing axonal degeneration in
patients with neurological diseases
Sold to Lilly (NYSE: LLY) Oct 2020
Novel therapeutics using proprietary
computational chemistry –
Sold to Allergan (NYSE: AGN) Sep 2016
Novel bicyclic peptides (bicycles) and
bicycle drug conjugates for cancer
IPO May 2019 (NASDAQ: BCYC)
Targeting the DNA damage
response pathway to prevent and
halt expansion repeat disorders
Pioneering targeted therapies
for serious muscle diseases –
IPO Sep 2020 (NASDAQ: DYN)
Transforming stem cell transplant
therapy for auto-immune and blood-
based diseases (NASDAQ: MGTA)
Precision therapeutics for
genetically-defined age-related
macular degeneration and rare diseases
Novel antibodies built to break
through the tumor microenvironment
IPO Apr 2018 (NASDAQ: SURF)
Mouse platforms for the generation
of fully human antibodies –
Sold to Harbour BioMed Dec 2016
Harnessing the power of microglia
to transform treatments for
neurodegenerative diseases
